The ADE risk commonly cited in the 2012 paper was specific to the nucleocapsid protein (N protein). With the N protein showing highest ADE potential and the S protein being critical to cellular entry via ACE2 binding, the S protein became the go-to target for nearly all the vaccine candidates at the beginning of the pandemic.
So yes, ADE was absolutely taken into account with these vaccines. If anyone is worried about antibody dependent enhancement, there is far less risk of that with the vaccines (which only expose your immune system to the S protein) than there is with getting a COVID-19 infection (which exposes your body to ALL the viral proteins).
Thank you for clarifying the fact that the ADE [Antibody Dependent Enhancement] was recognized and accounted for.
The URL I attempted to post was https://cen.acs.org/content/cen/articles/98/i38/tiny-tweak-behind-COVID-19.html?fbclid=IwAR0tTbiWYgr8H7qDX8H9Oe9x_TSLs6W0spyhgXn9G9e_ixKWH-MDUISyoa8.